An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Ibrutinib (Primary) ; Itacitinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 12 Jan 2017 Status changed from not yet recruiting to recruiting.
- 09 Dec 2016 Planned initiation date changed from 1 Sep 2016 to 1 Dec 2016.
- 05 May 2016 New trial record